Leukotrienes inhibit early stages of HIV-1 infection in monocyte-derived microglia-like cells by Bertin, Jonathan et al.
RESEARCH Open Access
Leukotrienes inhibit early stages of HIV-1
infection in monocyte-derived microglia-like cells
Jonathan Bertin, Corinne Barat, Dave Bélanger and Michel J Tremblay
*
Abstract
Background: Microglia are one of the main cell types to be productively infected by HIV-1 in the central nervous
system (CNS). Leukotriene B4 (LTB4) and cysteinyl-leukotrienes such as LTC4 are some of the proinflammatory
molecules produced in infected individuals that contribute to neuroinflammation. We therefore sought to
investigate the role of leukotrienes (LTs) in HIV-1 infection of microglial cells.
Methods: To evaluate the role of LTs on HIV-1 infection in the CNS, monocyte-derived microglial-like cells (MDMis)
were utilized in this study. Leukotriene-treated MDMis were infected with either fully replicative brain-derived HIV-1
isolates (YU2) or R5-tropic luciferase-encoding particles in order to assess viral production and expression. The
efficacy of various steps of the replication cycle was evaluated by means of p24 quantification by ELISA, luciferase
activity determination and quantitative real-time polymerase chain reaction (RT-PCR).
Results: We report in this study that virus replication is reduced upon treatment of MDMis with LTB4 and LTC4.
Additional experiments indicate that these proinflammatory molecules alter the pH-independent entry and early
post-fusion events of the viral life cycle. Indeed, LT treatment induced a diminution in integrated proviral DNA
while reverse-transcribed viral products remained unaffected. Furthermore, decreased C-C chemokine receptor type
5 (CCR5) surface expression was observed in LT-treated MDMis. Finally, the effect of LTs on HIV-1 infection in
MDMis appears to be mediated partly via a signal transduction pathway involving protein kinase C.
Conclusions: These data show for the first time that LTs influence microglial cell infection by HIV-1, and may be a
factor in the control of viral load in the CNS.
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Background
Infection of the central nervous system (CNS) by human
immunodeficiency virus type 1 (HIV-1) causes neuro-
toxicity and inflammatory disorders such as encephalitis
a n da s s o c i a t e dn e u r o c o g n i t ive deficits [1]. Since the
introduction of highly active antiretroviral therapy
(HAART) as the standard of care for seropositive
patients, the incidence of severe neurological complica-
tions caused by HIV-1 such as dementia has greatly
diminished, but a more subtle form of CNS dysfunction
known as minor cognitive and motor disorder has
emerged [2]. Although a discordance between cere-
brospinal fluid (CSF) and plasma viral load is often
observed, sustained virus replication in the CNS despite
suppressive antiretroviral therapy correlates with acute
or subacute neurological alterations [3-5]. Moreover, the
viral strains present in the CNS may, over time, geneti-
cally differ from virus isolates circulating in peripheral
blood [6]. Unsuppressed virus replication in the brain
favors the emergence of drug-resistant viruses and the
appearance of viral variants with reduced dependence
for CD4, the primary cellular receptor for HIV-1 [7].
Nevertheless, some studies have shown that the level of
CNS penetration in patients receiving HAART does not
significantly influence clinical efficacy [1,8], although
this issue remains controversial [9].
Entry of HIV-1 into the CNS occurs very early after
primary infection [10]. The Trojan horse model pro-
poses that HIV-1 can cross the blood-brain barrier
(BBB) through monocytes carrying virions and then be
liberated into the CNS [11-13]. Also, it has been
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endotoxin lipopolysaccharide (LPS) in the plasma of
HIV-1-infected patients, in combination with several
cytokines, viral proteins and eicosanoid lipid mediators,
increase permeability of the BBB, thus facilitating inva-
sion of HIV-1 into the CNS [11,14,15]. There, perivascu-
lar macrophages and microglia, along with astrocytes to
some extent, are the cells permissive to HIV-1 infection;
they also act as long-lived viral reservoirs despite anti-
viral therapies [6,16-20].
Leukotrienes (LTs), which are classified as eicosanoids,
are among the first soluble factors produced by the
innate immune system when challenged by an invading
pathogen. These potent proinflammatory lipid mediators
display strong vasoconstrictive, chemotactic and prolif-
erative properties. They are associated with different
inflammatory diseases, such as asthma, rhinitis and
atherosclerosis. In stimulated cells, the enzyme 5-lipoxy-
genase (5-LO) initiates synthesis of LTs from arachido-
nic acid. A short-lived LT precursor, LTA4,i sc o n v e r t e d
into either leukotriene B4 (LTB4) or cysteinyl-LTs
(cysLTs), the latter includes LTC4,L T D 4 and LTE4.
CysLTs engage CysLT-1, CysLT-2 and GPR17 receptor
subtypes, whereas LTB4 exerts its biological action by
means of cell surface receptors denoted as BLT1 and
BLT2, all of which belong to the family of G-protein-
coupled receptors [21,22]. BLT1 is expressed primarily
in leukocytes while BLT2 is expressed more ubiquitously
[23,24]. It should be stated that both CysLT-1 and
CysLT-2 are expressed in many cell types, including
cells of the monocyte/macrophage lineage [25]. Engage-
ment of LT receptors on microglia is associated with
release of the multifunctional nucleotide adenosine-5’-
triphosphate (ATP) and of cysLTs [26]. Furthermore,
the increase of LT synthesis in microglial cells following
LT-receptor activation requires the intracellular second
messenger p38 MAP kinase (MAPK) [27].
Several studies have reported that LTs, along with
their cognate receptors, are expressed in the brain
[22,26,28-35]. Moreover, in vitro cocultures of HIV-1-
infected monocytes and astroglia secrete high levels of
eicosanoids such as LTB4 and LTD4, which largely con-
tribute to neuroinflammation and neuronotoxicity [36].
In vivo, it has been reported that elevated amounts of
LTB4 can be found in the CSF of patients with AIDS
[37]. Moreover, recent studies have shown that
increased levels of 5-LO and high concentrations of
eicosanoids, including LTB4, are found in the brain of
HIV-1 transgenic rats [38,39]. Moreover, it has been
demonstrated that activated microglia can produce sev-
eral proinflammatory cytokines, chemokines and certain
eicosanoid metabolites [29,40-42]. In turn, chemotactic
molecules secreted in neuropathologic conditions, such
as LTs, contribute to the recruitment of potentially
infected leukocytes (including monocytes and lympho-
cytes) into the CNS [43]. However, LTs have also been
reported to indirectly exert anti-HIV-1 properties. For
example, LTB4 induces the release by neutrophils of
antimicrobial proteins, including a-defensins, that inhi-
bit HIV-1 infectivity [44,45].
We therefore tested whether LTs can modulate virus
infection in human microglial cells, which are known to
play a pivotal role in the neuropathogenesis of HIV-1.
Studies were performed using a previously described
experimental cell system based on primary human
monocyte-derived microglial-like cells (MDMis). We
report herein that LTB4 and LTC4 negatively modulate
s o m ee a r l ye v e n t si nH I V - 1i n f e c t i o ni nM D M i sa n d
that this effect relies at least partly on protein kinase C
(PKC).
Methods
Reagents
LTB4,L T C 4 and their respective less active metabolites
(that is, N-acetyl LTE4 and 20-carboxy-LTB4)w e r ea l l
purchased from Cayman Chemical (Ann Arbor, MI,
USA). Granulocyte macrophage colony-stimulating fac-
tor (GM-CSF) was a generous gift from Cangene (Win-
nipeg, Manitoba, Canada), whereas macrophage colony-
stimulating factor (M-CSF) was purchased from Gen-
Script Corporation (Piscataway, NJ, USA). The luciferase
activity assay was carried out using the D-luciferin
reagent purchased from Thermo Fisher Scientific (Rock-
ford, IL, USA). Slot blots to quantify substance P in cell-
free supernatants were revealed with the Western light-
ning plus ECL purchased from PerkinElmer (Waltham,
MA, USA). The PKC inhibitor bisindolylmaleimide IX
(also called Ro318220) was obtained from EMD Chemi-
cals (Gibbstown, NJ, USA). The two LT receptor
antagonists LY293111 and Bay-u9773 were purchased
from Cayman Chemical.
Antibodies
The anti-HIV-1 p24 hybridomas 31-90-25 and 183-H12-
5C were obtained from the American Type Culture Col-
lection (ATCC) (Manassas, VA, USA) and the NIH
AIDS Repository Reagent Program (Bethesda, MD,
USA), respectively. Antibodies were purified by using
MAbTrap protein affinity columns according to the
manufacturer’s instructions (Amersham Pharmacia Bio-
tech AB, Uppsala, Sweden). Differentiation of primary
human monocytes into MDMis was assessed using an
antibody specific for the ionized calcium binding adap-
tor protein 1 (IBA1) (Wako Chemical, Richmond, VA,
USA) followed with a goat anti-rabbit antibody labeled
with the Alexa Fluor
® 555 dye (Molecular Probes,
Eugene, OR, USA). Detection of substance P was
assessed using the rabbit polyclonal anti-substance P
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horseradish peroxidase (HRP)-conjugated goat anti-rab-
bit antibody (Jackson Immunoresearch, West Grove, PA,
USA). LT receptor expression was determined by flow
cytometry using either a rabbit anti-cysLT2 antibody
(Cayman Chemicals) followed by a goat anti-rabbit anti-
body conjugated with Alexa Fluor
® 488 (Molecular
Probes) or a biotinylated anti-BLT1 antibody (Cayman
Chemical) followed by a streptavidin-R-phycoerythrin
conjugate (BD Bioscience, Mississauga, Canada). C-C
chemokine receptor type 5 (CCR5) expression on
MDMis was assessed using the R-phycoerythrin-conju-
gated anti-CCR5 antibody (clone 2D7) purchased from
BD Bioscience.
Plasmids
The brain-derived full-length R5-tropic YU2 and X4-
using NL4-3 infectious molecular clones of HIV-1 were
obtained through the AIDS Research and Reference
Reagent Program (pYU2 from Dr Beatrice Hahn and Dr
George Shaw and pNL4-3 from Dr Malcolm Martin)
[46,47]. The pNL4-3Balenv is a full-length infectious
molecular clone of HIV-1 (kindly provided by R Pomer-
antz, Thomas Jefferson University, Philadelphia, PA,
USA) [48]. This virus is an R5-using viral strain where
the NL4-3 env gene has been replaced with the env
gene from the R5-tropic Bal variant. As for the NL4-
3Luc
+Env
-R
+ vector, kindly provided by Dr NR Landau
(NYU School of Medicine, New York, NY, USA), it pro-
duces envelope-deficient HIV-1 particles coding for the
luciferase reporter gene. Single-cycle reporter viruses
were pseudotyped with JR-FL envelope or vesicular sto-
matitis virus envelope glycoprotein G (VSV-G) leading
to NL4-3Luc
+Env
-R
+/JR-FL and NL4-3Luc
+Env
-R
+/VSV-
G pseudotypes, respectively. The R5-tropic envelope-
encoding JR-FLenv vector was kindly supplied by Dr NR
Landau, whereas pHCMV-G, which was obtained from
the AIDS Repository Reagent Program, codes for the
broad host-range VSV-G under the control of the
human cytomegalovirus promoter.
Cell culture
In order to obtain astrocyte-conditioned medium
(ACM), normal human astrocytes were cultured in
astrocyte basal medium supplemented with astrocyte
growth medium. Primary human astrocytes and media
were purchased from Lonza (Walkersville, MD, USA).
At 80% cellular confluence, the medium was harvested,
filtered (0.22 μm) and aliquoted. Aliquots of all passages
were kept at -80°C up to the tenth passage. This ACM
was then tested to determine the optimal percentage for
differentiating primary human monocytes into MDMis.
Briefly, peripheral blood mononuclear cells (PBMCs)
from healthy donors were isolated by Ficoll-Hypaque
gradient (Wisent Inc., St-Bruno, Qc, Canada). Next,
cells were plated at a final concentration of 1 × 10
7
cells/ml in 75 cm
2 flasks (BD Bioscience, Mississauga,
ON, Canada) for 2 h in order to separate by adherence
monocytes from the other non-adherent cells. After
washing with endotoxin-free phosphate-buffered saline
(PBS) (Sigma-Aldrich, Oakville, ON, Canada), mono-
cytes were cultured in complete RPMI-1640 medium
(that is, RPMI supplemented with 10% heat-inactivated
fetal bovine serum (FBS), 100 U/ml penicillin G and 100
μg/ml streptomycin) in the presence of M-CSF (10 ng/
ml) and GM-CSF (1 ng/ml) for 2 days. Cells were then
recovered with a soft cell scraper and plated in 24-well
plates (BD Bioscience, Mississauga, ON, Canada) at a
final concentration of 1 × 10
5 cells per well in complete
RPMI-1640 medium supplemented with M-CSF (10 ng/
ml), GM-CSF (1 ng/ml) and with (to obtain MDMis) or
without (to be used as control cells) an optimized per-
centage of ACM (ranging from 25% to 35%). To confirm
that ACM-treated monocytes display a cell phenotype
resembling microglial-like cells, after 14 days of expo-
sure to ACM the morphology of non-fixed cells was
examined by phase-contrast microscopy (Nikon Eclipse
TE300). After differentiation, MDMis were cultured in
RPMI supplemented with 10% heat-inactivated FBS, 100
U/ml penicillin G and 100 μg/ml streptomycin (Invitro-
gen, Burlington, ON, Canada).
Human embryonic kidney 293T (ATCC) and TZM-bl
cells (NIH AIDS Research and Reference Reagent Pro-
gram) were cultured in complete Dulbecco’s modified
Eagle’s medium (DMEM) (that is, DMEM supplemented
with 10% heat-inactivated FBS, 2 mM L-glutamine, 100
U/ml penicillin G and 100 μg/ml streptomycin).
Immunofluorescence microscopy for microglia
characterization
Cells were seeded onto glass coverslips (12 mm round,
thickness #1, Fisher Scientific, Nepean, ON, Canada) set
in 24-well plates at 1 × 10
5 cells per well and treated
with ACM for 14 days 2 days after peripheral blood
monocytes were isolated and incubated in the presence
of M-CSF and GM-CSF. Once monocytes were derived
into MDMis, cells were first fixed with 4% (w/v) room
temperature paraformaldehyde-PBS for 20 minutes and
next treated with a blocking solution (PBS supplemen-
ted with 1% bovine serum albumin (BSA), 0.2% Triton,
30% normal goat serum and 15% human serum) for 15
minutes followed by an incubation with a rabbit anti-
IBA1 antibody (diluted 1:500) in PBS containing 1%
BSA at room temperature for 1 h. After washing, cells
were incubated with goat anti-rabbit antibody conju-
gated with Alexa-555 (dilution 1:500) at room tempera-
ture for 30 minutes. After washing, coverslips were
mounted on microscope slides using Fluoromount-G
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and dried overnight in the dark. Cells were observed
using a Nikon Eclipse TE300 microscope.
Virus production
Viruses were produced by the calcium phosphate copre-
cipitation method in 293T cells as described previously
[49]. In brief, 293T cells were transiently transfected
with pYU2 to produce fully infectious R5-tropic HIV-1
particles. In addition, 293T cells were cotransfected with
pNL4-3Luc
+Env
-R
+ and either pJR-FLenv or pHCMV-G
to obtain pseudotyped HIV-1-based reporter viruses.
Virus preparations were normalized for virion content
by using an in-house enzymatic assay specific for the
major viral p24 protein. In this test, hybridomas 183-
H12-5C and 31-90-25 are used in combination to quan-
tify p24 levels [50]. In addition, the infectivity of our
v i r u ss t o c k sw a sa s s e s s e du s ing TZM-bl indicator cells.
This cell line is a genetically modified HeLa-derived cell
line expressing large amounts of cell surface CD4, CCR5
and C-X-C chemokine receptor type 4 (CXCR4) [51].
These cells carry separate integrated copies of the luci-
ferase and b-galactosidase genes under the control of
the HIV-1 promoter and are highly susceptible to infec-
tion with different HIV-1 variants (both R5 and X4 tro-
pic). Virus preparations that did not allow sufficient
reporter gene activity were discarded.
HIV-1 infection
After cell differentiation, MDMis were washed exten-
sively with PBS, plated at 1 × 10
5 cells per well were
and incubated in a final volume of 400 μlo fR P M Is u p -
plemented with 10% heat-inactivated FBS, 100 U/ml
penicillin G and 100 μg/ml streptomycin. Cells were
treated with LTs either before (45 minutes) or after
infection (2, 24, or 48 h) with luciferase-encoding pseu-
dotyped viruses. As for infections using a fully replica-
tive virus (that is, YU2), cells were treated with LTs
both before and after infection where a fraction of the
medium was removed (50 μl) every 3 days and for a
period lasting 9 days and kept frozen at -20°C. Virus
infection was performed with a fixed amount of virus
(that is, 10 ng of p24 per 1 × 10
5 cells) for 2 h and cells
were washed to remove excess virus. Virus production
was estimated by measuring p24 levels in cell-free cul-
ture supernatants by ELISA. Luciferase activity was mea-
sured 7 days after infection using an MLX microtiter
luminometer (Dynex Technologies, Chantilly, VA, USA)
and is expressed as relative luciferase units (RLU). In
some experiments, cell-free supernatants from MDMis
either left untreated or treated with LTs and next
infected with HIV-1 for 9 days were collected and virus
infectivity was defined upon incubation with TZM-bl
indicator cells.
Flow cytometry analysis
Before staining, cells were incubated for 15 minutes at
4°C in PBS containing 0.1% sodium azide, 10% heat-
inactivated human fibrin-depleted plasma, 10% normal
goat serum (Jackson ImmunoResearch Laboratories,
West Grove, PA, USA) and 10% FBS to block non-spe-
cific binding sites and washed once with PBS containing
0.1% sodium azide and supplemented with 5% FBS. To
monitor cell surface expression of CCR5, BLT1, BLT2,
cysLT1 and cysLT2, MDMi samples, treated or not with
LTs as indicated, were incubated with specific antibodies
or with an appropriate isotype-matched irrelevant con-
trol antibody (for non-specific staining) for 30 minutes
at 4°C, or for 20 minutes at room temperature excep-
tionally for CCR5. Cells were then washed with PBS
supplemented with 0.1% sodium azide and 5% FBS and
fixed in a 2% paraformaldehyde solution before analysis
by flow cytometry (Epics ELITE ESP; Coulter
Electronics).
Substance P detection
Cell-free supernatants were obtained from monocytes
cultured with or without ACM and blotted onto a 0.2
μm polyvinylidene fluoride (PVDF) membrane (Milli-
pore, Billerica, MA, USA) using a vacuum slot blotter.
The membrane was then blocked by incubation in PBS
containing 5% dried milk and 0.2% Tween-20 for 2 h
and then probed with polyclonal rabbit antibody to sub-
stance P (1:500) at 4°C overnight. Membranes were then
washed four times for 15 minutes in PBS containing
0.2% Tween-20 and incubated for 1 h with HRP-conju-
gated goat-anti-rabbit IgG (1:20,000). After 2 h of wash-
ing in PBS containing 0.2% Tween-20, the reaction was
visualized with the enhanced chemiluminescence system
(ECL plus) as recommended by the manufacturer. Signal
intensity on the film was quantified with densitometric
analysis software (ImageJ).
Real-time polymerase chain reaction (PCR)
For detection and quantification of reverse transcripts
and integrated viral DNA copies, MDMis (1 × 10
6) were
pulsed for 2 h with a virus preparation (that is, YU2)
previously treated with 20 U/ml grade II DNase-1
(Roche Applied Science, Qc, Canada). Cells were then
either left untreated or treated for 8 h (transcripts) or
24 h (proviral DNA) with LTs (10 ng/ml). Genomic
DNA was extracted using the DNeasy Blood and Tissue
Kit from Qiagen (Toronto, ON, Canada). Quantification
of HIV-1 reverse transcripts was achieved by real-time
PCR in a 25 μlr e a c t i o nc o n t a i n i n g2 5n go fD N A ,T a q -
Man Universal PCR Master Mix (Applied Biosystems,
Foster City, CA, USA), 1 μM each of HIV-1-specific
sense M667 and antisense M661 primers and 0.3 μMo f
the TaqMan probe HIV-5’-carboxyfluorescein (Biosearch
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integrated viral DNA copies, DNA was subjected to a
combined Alu-HIV-1 PCR and real-time PCR as
described previously [53]. Briefly, genomic DNA (100
ng) was first amplified with an Alu-sequence-specific
sense primer and HIV-1-specific antisense primer (that
is, M661) [54]. Next, 5 μl of 20-fold diluted PCR pro-
ducts were subjected to a real-time PCR assay in a 25 μl
reaction containing TaqMan Universal PCR Master Mix,
2 μM of the HIV-1-specific sense primer M667, 2 μM
of the HIV-1-specific antisense primer AA55 and 0.3
μM of the TaqMan probe HIV-5’-carboxyfluorescein
(Biosearch Technologies) [53]. We used a standard
curve made of known amounts of input viral DNA (that
is, pNL4-3 ranging from 469 to 30,000 copies). All HIV-
1 standards contained 1 ng of DNA from uninfected
cells as carrier. To quantify 2LTR circles, 125 ng of
DNA per 5 μl was subjected to a real-time PCR reaction
containing TaqMan Universal PCR Mix, 2 μMo ft h e
HIV-1 2LTR-specific primers (sense: CCCTCAGA-
CCCTTTTAGTCAGTG; antisense: TGGTGTGTAGTT
CTGCCAATCA) and 0.3 μM of the TaqMan probe
2LTR-FAM (GGA TCT ACC ACA CAC AAG GCT
TCC) [53]. To ensure quantification precision, all HIV-1
real-time PCR amplified samples were normalized using
the b-globin housekeeping gene. From every diluted
DNA samples, b-globin was quantified using 1 μMo f
sense (TGGTCTATTTTCCCACCCT) and antisense
(TGGCAAAGGTGCCCTTGA) specific primers and 0.3
μM of the TaqMan probe 5’-b-globin-CAL Fluor 560
(TCTGTCCACTCCTGATGCTG-BHQ-1 3’) (Biosearch
Technologies). Equal parts of every sample were pooled
and successive twofold dilutions were used as a relative
standard curve for b-globin quantification. The cycling
conditions used for the Applied Biosystems 7500
sequence detection system included a hot start (50°C for
2 minutes and 95°C for 10 minutes), followed by 40
cycles of denaturation (95°C for 1 minute) and extension
(63°C for 1 minute) with end point acquisition.
Statistical analysis
All experiments were repeated at least three times and
each figure combines the results obtained with all the
different donors unless otherwise specified. The statisti-
cal significance of the difference between groups was
determined using the Student t test. Calculations were
made with Prism version 3.03 (GraphPad Software, Inc.
La Jolla, CA, USA). The P values < 0.05 were considered
statistically significant.
Results
Because of the limited access to primary microglial cells
isolated from human brain specimens, which renders
experimental approaches that require large quantities of
cells difficult to achieve, we turned to a previously
described experimental model system to study the possi-
ble modulatory role of LTs in HIV-1 infection in micro-
glia. This unique cellular model is capable of supporting
productive infection with HIV-1 [55]. Furthermore, this
in vitro model mimics infiltrating microglia [56,57], one
of the cell types mostly responsible for disseminating
HIV-1 in the CNS.
Validation of the cellular model
Microglial-like cells are characterized by a typical quies-
cent microglia morphology consisting in long branching
processes and a small cellular body. These cells also
express IBA1, which is an intracellular molecule marker
known to be abundantly expressed in microglia [58]. To
validate our cellular model, we first examined the mor-
phology of the cells, as well as their IBA1 expression
level. As expected, ACM-treated monocytes display typi-
cal microglia morphology following differentiation (Fig-
ure 1A) and express much higher levels of IBA1 than
non-ACM-treated cells (used as control cells) (Figure
1B). Substance P, the most abundant neurokinin in the
CNS, is secreted in significantly higher amounts by
microglia than monocyte-derived macrophages [59].
Indeed, our MDMi preparations were found to produce
considerably more substance P than non-ACM treated
monocytes (Figure 1C). Furthermore, MDMis were
found to be permissive to productive infection with the
brain-derived R5-using HIV-1 isolate YU2, but produced
less progeny virus than non-ACM-treated monocytes
(Figure 1D), which is in line with previous published
observations [55]. In addition, MDMis were found to be
refractory to infection with a prototypic X4-using HIV-1
variant (that is, NL4-3) (data not shown). Altogether,
these data show that our cellular model displays the
hallmarks of microglial-like cells.
We also analyzed the surface expression of LTB4 (that
is, BLT1 and BLT2) and cysLT receptors (that is,
cysLT1 and cysLT2) on MDMis. In our study, neither
BLT2 nor cysLT1 were detected on MDMis by flow
cytometry (data not shown). However, BLT1 and
CysLT2 were found to be expressed on these cells, albeit
at a moderate level, with mean fluorescence intensities
of 2,200 and 993, respectively (Figure 1E).
LTs decrease HIV-1 replication in MDMis
We next evaluated if LTs could modulate HIV-1 replica-
tion in MDMis. To do so, MDMis were initially treated,
or not, with either LTB4 or LTC4 and then infected
with the fully replicative R5-tropic strain YU2. Viral
production was monitored for a period of 9 days. It is
noteworthy that LTs were replenished during the
experiment (that is, at days 3 and 6) because they are
known to be very unstable. To make sure that the effect
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used as controls the two less active metabolites 20-car-
boxy-LTB4 (called 20-COOH LTB4)a n dN-acetyl LTE4
(called N-Ac LTE4). For example, the biological activity
of 20-carboxy-LTB4 is only 2.6% of that of LTB4 in
causing human leukocyte degranulation [60], whereas
N-Ac LTE4 is 100 times less potent than LTC4 as a
vasoconstricting agent [61]. Treatment of MDMis with
LTB4 and LTC4 causes a diminution in HIV-1 infection,
as assessed by p24 values, to a greater extent than when
using the less potent catabolites (Figure 2A, B). To vali-
date whether the LT-mediated decrease in p24 levels
correlates with a diminution of virus infectivity, super-
natants were transferred onto TZM-bl indicator cells.
The relative infectivity was assessed by comparing the
luciferase activity generated by supernatants from YU2-
infected (that is, 9 days post infection) MDMis either
left untreated or treated with LTs or the less active ana-
logs. Data from Figure 2C revealed that production of
infectious virus is reduced in a more significant manner
by LTs (that is, 61% reduction with LTB4 and 74%
diminution with LTC4)c o m p a r e dt oM D M i st r e a t e d
with their less active analogs (20-COOH LTB4 and N-
Ac LTE4, respectively), which is in agreement with p24
values. The colorimetric MTS assay revealed no toxicity
mediated by LTs in MDMis at the highest concentration
tested (that is, 100 ng/ml) for a period of 9 days (data
not shown).
Figure 1 Characterization of microglial-like cells. Monocytes were isolated from peripheral blood mononuclear cells (PBMCs) of healthy
donors, and then cultured either in absence or presence of astrocyte-conditioned medium (ACM). (A) Cell morphology was observed by phase-
contrast microscopy. Monocytes cultured in the absence of ACM were used as control cells. The results shown are representative of at least
three different donors. (B) ACM-differentiated cells were permeabilized and stained with anti-ionized calcium binding adaptor protein-1 (IBA1)
antibodies. IBA1 expression was observed by epifluorescence microscopy. The results shown are representative of at least three distinct donors.
(C) Substance P secretion by monocyte-derived microglial-like cells (MDMis) and non-ACM-treated control cells was evaluated by slot-blot.
Results from two independent donors (means ± SEM) are presented. (D) ACM-treated and non-treated monocytes were infected with YU2. Virus
replication was assessed by monitoring the p24 content at days 3, 6 and 9 post infection. The means ± SEM are calculated from three
independent experiments with triplicate samples. (E) The surface expression of BLT1 and cysLT2 receptors on ACM-treated monocytes was
determined by flow cytometry. The results shown represent a single donor out of a total of four.
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We next sought to determine which step(s) of the HIV-
1 life cycle LTs affected in MDMis. This goal was
achieved by performing a timecourse experiment with
luciferase-encoding single-cycle reporter viruses. More-
over, to define whether LTs can alter the process of
virus entry, MDMis were inoculated with both R5 (that
is, JR-FL envelope) and VSV-G pseudotyped reporter
viruses. This is based on the idea that VSV-G pseudo-
types enter cells by a pH-dependent endocytosis process
and independently of the natural pH-independent path-
way that relies on HIV-1 receptor and coreceptors. As
shown in Figure 3, treatment of MDMis with LTs prior
to virus infection reduced infection with JR-FL
pseudotypes in a dose-dependent manner (A), whereas
infection with reporter viruses pseudotyped with VSV-G
was left unaffected (B), therefore suggesting that the
initial steps in the replicative cycle of HIV-1 in MDMis
are negatively affected by LTs. However, infection by
both JR-FL and VSV-G pseudotypes was reduced when
LTs were added to MDMis at 2 h or 24 h post infection
(with the strongest effect seen at 2 h post infection),
thus suggesting that a post-fusion step is also affected
by LT treatment. The late infection stages (that is, after
viral integration) are not touched by LTs since no signif-
icant modulatory effect was seen when cells were treated
at a later time point (that is, 48 h post infection).
Although a greater inhibition was observed when using
a final concentration of 100 ng/ml of LTs, the more
P
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Figure 2 Leukotrienes (LTs) reduce susceptibility of monocyte-derived microglial-like cells (MDMis) to HIV-1 infection. (A) MDMis were
pretreated for 45 minutes with 100 ng/ml of the indicated LTs prior to infection with YU2. At 2 h after infection, cells were then thoroughly
washed and incubated in fresh media containing the listed LTs. Additional LTs were also replenished at days 3 and 6 post infection. Viral
production was monitored at 3, 6 and 9 days post infection by measuring the p24 content. The results shown are from one representative
donor of a total of three. (B) The p24 values for all three donors tested are depicted as percentage of untreated control to compensate for
donor-to-donor virus infection variability. (C) Production of infectious virus particles by LT-treated MDMis was quantified at 9 days post infection
in cell-free supernatants using the TZM-bl indicator cell line. Results shown represent mean luciferase activity ± SD calculated from three
independent experiments with triplicate samples and are expressed as the relative percentage of infectious virus production with respect to
non-treated cells (*P < 0.05).
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Page 7 of 15physiological concentration of 10 ng/ml was used in
subsequent experiments.
To further validate that LTB4 and LTC4 must engage
their respective receptors in order to modulate the early
steps of HIV-1 replication, MDMis were treated with
potent LT receptor antagonists prior to LT treatment
and infection with JR-FL pseudotypes. To this end,
LY293111 was used to block BLT1 while Bay-u9773 was
used to block cysLT1/2. Results show that the LTB4/
LTC4-induced inhibition of viral production in MDMis
is totally abolished by LY293111 or Bay-u9773, respec-
tively (Figure 4).
LTB4 and LTC4 downregulate surface expression of CCR5
on MDMis
Because pretreatment of MDMis with LTs affects infec-
tion by JR-FL but not VSV-G pseudotypes, we hypothe-
sized that the pH-independent fusion step of the virus
life cycle is likely inhibited by LTs. We investigated
whether this could occur via a decrease in the
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Figure 3 Leukotrienes (LTs) exert an inhibitory effect on the early stages of HIV-1 infection in monocyte-derived microglial-like cells
(MDMis). Cells were either left untreated, or treated with increasing concentrations of LTB4 (left panels) or LTC4 (right panels), either 45 minutes
before virus exposure or 2 h to 48 h post infection, as indicated. Cells were first washed extensively with phosphate-buffered saline (PBS) and
then infected at 45 minutes after addition of LTs. MDMis were washed a second time at 2 h after infection before adding LTs. No washes were
carried out before adding LTs at 24 h and 48 h. Infection was carried out with a luciferase encoding reporter virus pseudotyped with JR-FL (A)
or vesicular stomatitis virus envelope glycoprotein G (VSV-G) envelope (B). The less active analogs (called LAA) 20-carboxy-LTB4 and N-acetyl LTE4
were used as negative controls for LTB4 and LTC4, respectively. The extent of virus infection was estimated by measuring virus-encoded
luciferase activity at 7 days post infection. The results shown represent the means ± SD calculated from three, or four (bottom right panel),
independent experiments with triplicate samples and are expressed as the percentage of luciferase activity with respect to non-treated cells (*P
< 0.05).
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Page 8 of 15expression of the HIV-1 coreceptor CCR5. Results
obtained by flow cytometry show that incubation of
MDMis in the presence of LTB4 or LTC4 for a 24-h
period caused a diminution in the percentage of MDMis
expressing CCR5 at the cell surface (Figure 5). Mean-
while, CCR5 expression remained unaffected after a 45-
minute incubation period (data not shown), which
points to an indirect effect on CCR5, rather than a
direct receptor heterologous desensitization. These data
suggest that LTs likely inhibit productive HIV-1 infec-
tion in MDMis partly via a modulation of CCR5 surface
expression.
LTs reduce virus integration
To gain insights on the nature of HIV-1 post-fusion
events modulated by LTs, we then analyzed the reverse
transcription and integration processes. Completed
reverse transcripts and proviral DNA were quantified by
real-time PCR in MDMis treated with LTs. Here, in
order to distinguish the post-entry events from the con-
sequences on the pH-independent viral entry at the
plasma membrane, cells were treated with LTs at 2 h
post infection. As shown in Figure 6, LTB4 and LTC4
had no significant impact on the amount of completed
HIV-1 reverse transcription products, whereas both LTs
induced a 50% reduction of integrated proviral DNA in
MDMis.
The effect of LTs on HIV-1 infection is reliant on PKC
It is known that treatment of cells with LTs is often
associated with PKC activation. Besides, Warrilow and
coworkers have shown that some PKC modulatory com-
pounds inhibit HIV-1 infection in PBMCs [62]. We
therefore evaluated the involvement of PKC in the LT-
mediated inhibitory effect on HIV-1 replication in
MDMis. To do so, MDMis were treated, or not, with
the large-spectrum PKC inhibitor Ro318220, prior to
their exposure to luciferase-encoding HIV-1 particles.
LTs were added on cells either 45 minutes before or 2 h
after infection, and luciferase activity was then measured
7 days post infection. Results illustrated in Figure 7A
demonstrate that the LT-induced modulation of HIV-1
infection in MDMis is abolished upon treatment with
the PKC inhibitor, indicating that a PKC-mediated sig-
nal transduction pathway is involved in that phenom-
enon. Furthermore, the fact that the effect is observed
whether LTs are added before or after infection indi-
cates that PKC is involved in both early and post-fusion
events of HIV-1 infection. To better define the involve-
ment of PKC in the LT-modulated inhibitory effect on
HIV-1 post-fusion events, we quantified both integration
events and the formation of 2LTR circles in MDMis
treated or not with the large spectrum PKC inhibitor
Ro318220 prior to their exposure to LTs. It is important
to note that the number of 2LTR circles serves as a
quantitative measurement for nuclear import. For this
set of experiments, VSV-G-pseudotyped viral particles
were used in order to achieve a high infection efficiency
that is necessary to detect the relatively rare 2LTR circle
intermediates. As illustrated in Figure 7B, the reduction
in intregrated proviral DNA in MDMis treated with the
studied LTs is totally abolished following Ro318220
treatment. Moreover, a detectable reduction in the level
of 2LTR circles was also observed in LT-treated
MDMis, indicating a blockage at or before the nuclear
import steps of the viral replication cycle (Figure 7C).
However, Ro318220 failed to abolish this effect of LTs
on 2LTR in MDMis, which points to another PKC-inde-
pendent pathway that might also inhibit HIV-1 produc-
tion in MDMis.
Discussion
There is a paucity of data regarding the impact of
potent eicosanoid lipid mediators on HIV-1 replication.
Eicosanoids include four distinct families, that is, prosta-
glandins, prostacyclins, thromboxanes and LTs. Various
studies have shown that prostaglandins can induce cel-
lular resistance to HIV-1 [63-66]. As for LTs, only
recently have we considered them as antimicrobial or
Figure 4 Leukotriene (LT) receptor antagonists block the
modulatory effect of LTB4 and LTC4 on HIV-1 replication in
monocyte-derived microglial-like cells (MDMis). Cells were either
left untreated (Ctrl) or treated with the listed LT receptor
antagonists (that is, LY293111 or Bay-u9773) for 45 minutes before
being thoroughly washed. MDMis were then either exposed to LTs
45 minutes before or 2 h following HIV-1 infection, after which cells
were thoroughly washed. Virus infection was carried out using JR-FL
pseudotyped viruses. The extent of virus infection was estimated by
measuring virus-encoded luciferase activity at 7 days post infection.
The results shown represent the means ± SD calculated from three
independent experiments with triplicate samples and are expressed
as the percentage of luciferase activity with respect to non-treated
cells (*P < 0.05).
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Page 9 of 15anti-HIV-1 mediators [44,45,59,67-70]. In the CNS in
particular, the interaction between LTs produced by
immune cells and HIV-1 infection is poorly understood.
We therefore focused our studies on the effect of LTs
on HIV-1 infection in microglial cells. We chose to con-
duct our experiments in MDMis since this novel in
vitro model mimics infiltrating microglia that are
subjected to productive HIV-1 infection under in vivo
situations.
To the best of our knowledge, other than one recent
publication [71] no further studies on MDMi cells have
been published following their initial characterization by
Leone and colleagues in 2006 [55]. For this reason, we
first validated our MDMis by verifying their
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Page 10 of 15morphology, IBA1 expression, substance P production
and susceptibility to HIV-1 infection. We also verified
the presence of LTB4 and LTC4 receptors on these cells.
We were thus able to test this novel cellular model,
which allowed us to overcome the difficulty of obtaining
primary human microglial cells in sufficient quantities.
We determined that both LTB4 and LTC4 decrease
productive HIV-1 infection of MDMis. More precisely,
LTs seem to negatively modulate the earliest as well as
post-fusion events. However, we were not able to
observe any effects on late stages of infection (48 h post
infection). The concentrations used in the current study
seem higher than the LT concentrations found in the
CSF in inflammatory conditions, which can vary
between 116 and 348 pg/ml [32,37]. However, levels of
LTs in CSF are probably an undervaluation of the
amount produced in brain tissue. Indeed, because LTs
can be secreted locally by glial cells, concentrations
s i m i l a ro rh i g h e rt ot h o s eu s e di no u rw o r ka r el i k e l y
reached in the microenvironment surrounding brain
microglial cells based on the notion that pg of LTs are
measured per g of brain tissue.
We examined whether the HIV-1 coreceptor CCR5
was affected by the studied LTs. Since we did not
observe any CCR5 modulation when MDMis were pre-
exposed to LTs for 45 minutes, LTs likely do not cause
CCR5 internalization by means of heterologous desensi-
tization, which is a mechanism of rapid internalization
of unstimulated G protein-coupled receptors that occurs
despite the continued presence of a ligand. However,
MDMis exposed to LTs for a longer period (24 h)
showed a dose-dependent decrease in CCR5 surface
expression. LT-treated MDMis might produce different
b-chemokines (for example, macrophage inflammatory
protein (MIP)-1a,M I P - 1 b and chemokine (C-C motif)
ligand 5 (CCL5, also known as RANTES)), which may
be responsible for the delayed CCR5 downmodulation
by means of homologous desensitization partly responsi-
ble for the negative effect of LTs on the production of
virion progeny. Further studies will be needed to pin-
point the exact mechanisms by which CCR5 is modu-
lated by LTs. Besides, it is possible that MDMis exposed
to LTs show attenuated levels of other surface molecules
known to play a role in HIV-1 infection in the CNS,
such as CCR3 or galactocerebroside (or galactosylcera-
mide). Although controversial, it has been shown that
LTB4 receptor could act as a coreceptor for HIV-1 in
CD4-positive cells [72,73]. If true, competition for LT
receptors might be one explanation for how LTs attenu-
ate HIV-1 replication in MDMis.
The early stages of HIV-1 replication include all steps
from binding at the cell surface to integration into the
nucleus [74]. At the post-entry level, these early events
consist of viral decapsidation, reverse transcription,
nuclear import and integration. Interestingly, the strongest
inhibition with respect to HIV-1 replication in MDMis
was measured when target cells were exposed to LTs 2 h
post infection, which is after virus entry. Thus, early post-
entry events may also be targeted. We indeed detected
lower amounts of integrated viral DNA in MDMis
exposed to LTs 2 h following their infection, while the
reverse-transcribed products remained unaffected. These
data suggest that post-entry inhibition of HIV-1 infection
by LTs in MDMis occurs between the reverse transcrip-
tion and integration steps. Nuclear import of the HIV-1
genome is mediated by a central HIV-1 DNA flap that is
formed at the end of reverse transcription [75]. This
three-stranded DNA structure is necessary for the
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Page 11 of 15uncoating process that characterizes the maturation of
reverse transcribed complexes into preintegration com-
plexes [76]. Little is known about the regulation of such
events by host cell factors. It is possible that signals trans-
duced from LT receptors interfere with the formation of
the DNA flap or the uncoating process. Further research
will be needed to investigate these possibilities.
Interestingly, previous studies have shown that PKC
modulatory compounds can affect the early events of
HIV-1 infection in PBMCs [62]. Incubation of MDMis
with a large spectrum PKC inhibitor abolished the effect
of LTs on HIV-1 infection both at the early and post-
fusion levels. PKC thus act as second messengers
responsible for the LT-mediated reduction in HIV-1
A
C B
Time of LT addition:
Ro318220:
45 min
Pre-infection
2 h
Post-infection
I
n
f
e
c
t
i
o
n
 
l
e
v
e
l
(
p
e
r
c
e
n
t
a
g
e
 
o
f
 
C
t
r
l
)
I
n
t
e
g
r
a
t
i
o
n
 
e
v
e
n
t
s
(
p
e
r
c
e
n
t
a
g
e
 
o
f
 
C
t
r
l
)
2
L
T
R
 
q
u
a
n
t
i
f
i
c
a
t
i
o
n
(
p
e
r
c
e
n
t
a
g
e
 
o
f
 
C
t
r
l
)
Ro318220: Ro318220:
Ctrl Ctrl LTB4 LTB4 LTC4 LTC4 Ctrl Ctrl LTB4 LTB4 LTC4 LTC4
Figure 7 Leukotrienes (LTs) reduce HIV-1 infection of monocyte-derived microglial-like cells (MDMis) in a protein kinase C (PKC)-
dependent manner. (A) MDMis were first either left untreated or treated with the large-spectrum PKC inhibitor Ro318220 (1 μM) for 30
minutes. LTs (10 ng/ml) were then added to cells either for 45 minutes before infection or after 2 h of incubation with JR-FL pseudotypes.
Luciferase activity was measured 7 days post infection. (B, C) MDMis were first infected with vesicular stomatitis virus envelope glycoprotein G
(VSV-G) pseudotypes for a 2 h period, cells were then treated with Ro318220 for 45 minutes, washed, and treated with LTs (100 ng/ml). Total
DNA was extracted from cells in order to quantify HIV-1 integration events (panel B) and nuclear 2LTR circles (C) by real-time polymerase chain
reaction (PCR). The results shown are expressed as percentages of control (that is, untreated cells) and calculated from five (A) or two (B, C)
independent experiments in triplicate samples (*P < 0.05).
Bertin et al. Journal of Neuroinflammation 2012, 9:55
http://www.jneuroinflammation.com/content/9/1/55
Page 12 of 15infection. There are 12 PKC isozymes distributed either
in the conventional (require calcium, diacylglycerol and
phospholipids for activation), novel (require diacylgly-
cerol for activation) or atypical (require neither calcium
nor diacylglycerol for activation) subfamilies. Although
it is not yet known which PKC isozymes are expressed
in MDMis, LT stimulation could activate any of these
PKC in this cellular model. Additional studies will be
needed to identify which PKC isozymes and what down-
stream signals are implicated in the inhibition of HIV-1
in MDMis by LTs. To determine more precisely which
post-fusion step is inhibited by LTs in MDMis via PKC,
we measured integrated viral DNA and nuclear 2LTR
circles. We found that integrated proviral DNA is
diminished by LTs in a PKC-dependent manner while
2LTR levels are decreased independently of the PKC sig-
naling pathway in MDMis. Consequently, it can be pro-
posed that LTs block the integration process after
formation of the 2LTR circles in the nucleus by a
mechanism that is partly mediated by PKC, but a reduc-
tion of the nuclear import via a PKC-independent path-
way cannot be excluded. Nuclear import of the HIV-1
preintegration complex depends on members of the cell
nuclear transport machinery such as karyopherin b
transportin-3 (TNPO3) and nucleoporin 153 (NUP153)
[77-79]. Interestingly, this nuclear transport machinery
is inhibited by phosphorylation via mitogen-activated
protein kinase kinase (MEK) and phosphatidylinositol 3-
kinase signaling [80]. It is possible that such signal
transduction pathways are induced by LT treatment,
causing nucleoporin phosphorylation and inhibition of
nuclear import. Additional studies are needed to solve
this issue.
Conclusions
In summary, the goal of this study was to analyze the
possible involvement of LTs in the control of HIV-1
infection in microglia. The results of this study indicate
that LTB4 and LTC4 inhibit some early events of the
HIV-1 replication cycle in MDMis and that this effect
relies on PKC. Now, if confirmed in vivo, what physiolo-
gical relevance would be presented by the observed
attenuation of HIV-1 infection by LTs? In the post-
HAART era, individuals still show mild symptoms of
neuroinflammation associated to HIV-1 infection. LTs,
among other proinflammatory molecules, are often
found in the CSF of patients who are infected with
HIV-1. Because of the high selectivity and low perme-
ability of the BBB, the CNS is under weak immunologi-
cal surveillance. However, viral load in the CNS is rarely
much higher than in peripheral blood. Neuroinflamma-
tion, accompanied by production of LTs, may play a
protective role against viral attack such as HIV-1. Since
microglia are largely responsible for productive HIV-1
infection in the CNS, the data presented here provide
an insight into how LTs may be one factor that help
control viral load in the CNS compartment. Although
some previous studies reported no adverse side effects
associated with intravenous injections of LTB4 to
humans or monkeys [44,45], additional research will be
needed to determine if LTs can be used as a treatment
or prophylaxis for HIV-1 infection. Thus, experimental
studies using in vivo models will be needed to clarify
the exact role of these proinflammatory lipid mediators
in the modulation of viral load in the CNS.
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